Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

November 10, 2005 09:00 ET

Holmes Herbs, Inc.: Qualia Completes Research Contract for Merck Pharmaceuticals

SCOTTSDALE, ARIZONA--(CCNMatthews - Nov. 10, 2005) - Holmes Herbs, Inc., (OTCBB:HMHB), announced today that its clinical research partner, Qualia Clinical Research Services Inc. ("Qualia"), recently completed a clinical research contract on behalf of Merck Pharmaceuticals.

The clinical research for Merck Pharmaceuticals involved a Phase 4 trial on Monteleukast. Merck is a leading research-driven pharmaceutical company engaged in discovering, developing, manufacturing and marketing medicines for human health.

Holmes also announced that it has retained The Insight Financial Marketing Network as its corporate communications agency in the United States. The Insight Financial Marketing Network (www.insightfmn.com) will work to increase awareness of Holmes's corporate growth strategy among investors and business media, plus assist in identifying an institutional financing.

Holmes Herbs Inc. is acquiring Qualia, a transaction expected to close on or before November 30, 2005.

On behalf of the Board of Directors

John F. Metcalfe, President and CEO

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.


Contact Information